EDEN PRAIRIE, Minn., Feb. 9, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fiscal first quarter 2023 ended December 31, 2022 and provide a corporate update on February 14, 2023 at 4:30 PM Eastern Time.
Conference Call and Webcast Information:
Tuesday, February 14, 2023 – 4:30 PM Eastern Time
Participant Dial-In:
877-405-1216 / 201-689-8336
Live Webcast:
Join here
Phone Replay:
877-660-6853 / 201-612-7415, Access ID: 13736384; available through February 28, 2023
Webcast Replay:
Available for 12 months
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.
Last Trade: | US$0.76 |
Daily Volume: | 89,171 |
Market Cap: | US$23.350M |
October 31, 2024 September 10, 2024 September 05, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB